Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

The Carlyle Group Inc. - Common Stock (NQ:CG)

63.11 +3.01 (+5.01%)
Streaming Delayed Price Updated: 1:06 PM EDT, Aug 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about The Carlyle Group Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Carlyle Exits Calastone As SS&C Expands Global Fund Reach
SS&C Technologies to acquire Calastone for $1.03 billion, expanding global fund distribution and automation. Expected to close in Q4 2025. 
Via Benzinga
3 No-Brainer Dividend Stocks to Buy With $200 Right Now
Via The Motley Fool
Topics Retirement
5 Analysts Assess Carlyle Group: What You Need To Know
 
Via Benzinga
Why KKR Stock Rocketed Almost 5% Higher Today
Via The Motley Fool
Topics Economy Government World Trade
Carlyle Group Stock: A Deep Dive Into Analyst Perspectives (11 Ratings)
 
Via Benzinga
Is Carlyle Group Gaining or Losing Market Support?
 
Via Benzinga
Price Over Earnings Overview: Carlyle Group
 
Via Benzinga
Earnings Scheduled For May 8, 2025
 
Via Benzinga
Earnings Scheduled For August 6, 2025
 
Via Benzinga
How Do Investors Really Feel About Carlyle Group?
 
Via Benzinga
CommScope Stock Is Trading Higher Monday: What's Going On?
CommScope shares are trading higher Monday after Amphenol announced it will acquire the company's Connectivity and Cable Solutions segment for $10.5 billion. 
Via Benzinga
Is the Market Bullish or Bearish on Carlyle Group?
 
Via Benzinga
Honeywell, Applied Materials, Carlyle Group And A Real Estate Stock On CNBC's 'Final Trades'
Honeywell is off 5% after solid earnings. The company topped on top and bottom lines and also raised guidance. 
Via Benzinga
Carlyle Confirms Deal To Buy Majority Stake In AI-Focused IT Consultancy Firm Adastra
Via Stocktwits
Is the Market Bullish or Bearish on Carlyle Group?
 
Via Benzinga
Earnings Scheduled For May 6, 2025
 
Via Benzinga
What's Driving the Market Sentiment Around Carlyle Group?
 
Via Benzinga
Earnings Scheduled For February 20, 2025
 
Via Benzinga
The Analyst Verdict: Carlyle Group In The Eyes Of 6 Experts
 
Via Benzinga
Carlyle CEO Harvey Schwartz Says 'Stay Buckled' Amid Market Turmoil – 'It's Just A Question Of Whether The Airbags Come Out
 
Via Benzinga
Wall Street Mixed Ahead Of Fed Meeting, Alphabet Sinks: What's Driving Markets Wednesday?
U.S. stocks traded mixed at midday Wednesday, as investors remained cautious ahead of the Federal Reserve’s upcoming policy decision, with Chair Jerome Powell set to speak at 2:30 p.m. ET. 
Via Benzinga
Topics Economy
Bill Miller's Q4 Additions Struggle Amid Market Uncertainty, What Else Is Dragging Them Down?
Bill Miller IV‘s investment firm has seen significant losses in its fourth-quarter portfolio additions as market uncertainties persist. 
Via Benzinga
Is Carlyle Group Gaining or Losing Market Support?
 
Via Benzinga
SoftBank Buys Silicon Valley Firm As It Goes All-In On AI
This is the third big AI move the bank has made this year. 
Via Talk Markets
Topics Artificial Intelligence Stocks / Equities
Masayoshi Son's SoftBank Buys Oracle-Backed Ampere For $6.5 Billion To Boost US AI Push
SoftBank has acquired Oracle-backed Ampere for $6.5 billion to strengthen its AI infrastructure strategy in the U.S., marking a major step in its broader push into Arm-based computing and large-scale... 
Via Benzinga
Topics Artificial Intelligence
Oppenheimer Analysts Slash Estimates For Goldman Sachs, Jefferies Amid Subdued M&A Activity
Analysts expect rebound in M&A and financing activity, but uncertainties may pause it. Estimates slashed for GS and JEF, CG downgraded to Perform. 
Via Benzinga
Tariffs Tangle Markets, Businesses, Investors
When uncertainty spikes, our ability to look out into the future shrinks. 
Via The Motley Fool
Bristol Myers Squibb Scoops Up Its Blood Cancer Drug Partner 2seventy Bio In $286 Million Deal
Bristol Myers Squibb to acquire 2seventy Bio for $5.00 per share in a $286 million all-cash deal, an 88% premium to its last close. Expected to close in Q2 2025. 
Via Benzinga
What's Going On With Gene Therapy Company Bluebird Bio Stock Today?
bluebird bio agrees to be acquired by Carlyle Group and SK Capital, offering stockholders up to $9.84 per share in a strategic buyout. 
Via Benzinga
US Stocks Dip As Powell Stays Cautious, Intel Climbs, Tesla Sinks To 11-Week Low: What's Driving Markets Tuesday?
U.S. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.